================================================================================
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
F O R M 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of March 2003
Prana Biotechnology Limited
(Name of Registrant)
Level 1, 100 Dorcas Street, South Melbourne, Victoria 3205 Australia
(Address of Principal Executive Office)
Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form 20-F [X] Form 40-F [ ]
Indicate by check mark if the registrant is submitting the Form 6-K in
paper as permitted by Regulation S-T Rule 101(b)(1):
Indicate by check mark if the registrant is submitting the Form 6-K in
paper as permitted by Regulation S-T Rule 101(b)(7):
Indicate by check mark whether by furnishing the information contained in
this Form, the registrant is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes [ ] No [X]
If "Yes" is marked, indicate below the file number assigned to the
registrant in connection with Rule 12g3-2(b): 82- ___________________
================================================================================
PRANA BIOTECHNOLOGY LIMITED
6-K Items
1. Prana Biotechnology Limited Appendix 4B Interim Financial Report for the 6
months ended December 31, 2002 dated March 13, 2003.
2. Prana Biotechnology Limited new issue announcement, application for
quotation of additional securities and agreement dated March 13, 2003.
ITEM 1
Appendix 4B
Prana Biotechnology Limited Half yearly report - 31 December 2002
--------------------------------------------------------------------------------
[GRAPHIC OMITTED][GRAPHIC OMITTED]
PRANA BIO TECHNOLOGY LIMITED
ABN 37 080 699 065
INTERIM FINANCIAL REPORT
31 December 2002
DIRECTORS' REPORT
The Directors of Prana Biotechnology Limited herewith submit the financial
report for the six months ended 31 December 2002. In order to comply with the
Corporations Act 2001, the Directors' report as follows:
DIRECTORS
The names of Directors who held office during or since the end of the financial
year are:
Geoffrey Kempler, Executive Chairman 11 November 1997
Professor Colin Masters, Executive Director 9 December 1999
Brian Meltzer, Non-Executive Director 9 December 1999
George Mihaly, Non-Executive Director 9 December 1999
THE RESULT
The operating loss for the Company for the half year amounted to $3,138,115
(prior half year loss $2,533,922)
REVIEW OF OPERATIONS
The Chairman and senior staff recently prepared a presentation to shareholders
covering achievements to date, goals for the current year and the outlook for
2003, an extract of the presentation is included below.
Overview
The three main points made at the presentation are:
1. Through preclinical and clinical proof of concept studies, MPACs have
established themselves as a revolutionary and exciting strategy to address
neurodegenerative diseases.
2. Our findings have been scrutinised and embraced by several global
Pharmaceutical companies who are keenly negotiating with Prana to establish
ongoing collaborations.
3. We have a significant head start in the development of intellectual
property to drive value into the hands of shareholders.
--------------------------------------------------------------------------------
Page 1 of 26
Appendix 4B
Prana Biotechnology Limited Half yearly report - 31 December 2002
--------------------------------------------------------------------------------
Extract of the Executive Chairman's presentation
Let me begin with a recap of the overall goals and purpose of the company. Prana
was established to develop drugs to treat the underlying toxicity associated
with aggregating proteins in the brain, beginning with Alzheimer's disease (AD).
We have evidence that our approach will help with a broad range of other major
neurodegenerative disorders. The toxicity is a consequence of this metal protein
interaction. Therefore our therapeutic strategy has been to develop drugs that
attenuate this activity between metals and proteins - a class of molecules
called MPAC's (metal-protein attenuating compounds).
The ideal drug for an AD patient would have 3 qualities:
1. Treat the symptoms - improve cognition in patients;
2. Treat the cause - address the underlying pathology of the disease; and,
3. Be suitable for long term use.
Current drugs on the market only partially arrest the symptoms over a limited
period of time, but do not stop the inexorable progression of the disease.
Nonetheless, even these drugs have combined sales of about a billion dollars.
So what is the hope for Prana's MPAC drugs? Prana's aim has always been to
develop the ideal drug that goes beyond existing drugs. Initially we selected
Clioquinol, an existing compound with MPAC attributes, to provide clinical proof
of concept. To test this we designed a small clinical trial and the results of
the trial strengthen our belief that MPAC's have the potential not only to
benefit cognition but also to positively influence the underlying causes of the
pathology of the disease.
These results have been shared, in confidence, with a select group of
international Pharmaceutical companies who have independently reviewed both the
scientific and clinical data and have provided us with independent confirmation
of the validity of the therapeutic approach. Their enthusiastic responses
provide us with the confidence to predict that the company will enter into a
significant collaboration with a suitable pharmaceutical company.
Share price and cash position
Let me comment on the recent share trading in Prana and our cash position. Prana
has raised a total of A$13million from the public to develop the company to this
point. At the time of the original IPO in Australia, back in March 2000,
original investors who subscribed for fully paid ordinary shares also received a
1:2 attaching Option to purchase an additional share in the company, exercisable
at 50 cents before the 1st of March this year. In the US Options are more
commonly know as Warrants. Investors have always been cogniscent that these
Options would be exercised and converted into shares. Accordingly the conversion
of these Options has always been anticipated in considering the underlying
market capitalisation of the company. It is important to note that the
conversion of these Options does not have a new dilutionary effect of the market
capitalisation of the company. The Company will receive approximately $3.5
million from the conversion of these Options, which is fully underwritten. We
believe the recent selling in Prana shares has arisen from some Option holders
having to sell a portion of their fully paid shares to fund the exercise of
their Options. Naturally, this pressure will be eliminated from March 1 onwards.
With regard to cash, this injection of $3.5 million, in addition to our existing
$1.4 million in cash and assured receipts from existing Grants, provides us with
operating funds for over a year. Further funding opportunities are under
evaluation for the period beyond that.
--------------------------------------------------------------------------------
Page 2 of 26
Appendix 4B
Prana Biotechnology Limited Half yearly report - 31 December 2002
--------------------------------------------------------------------------------
Extract from Chief Operating Officer and head of Drug Development's presentation
Prana clearly had an exciting and productive 2002. Most notable was the
completion of the Phase II "proof-of-concept" clinical trial with clioquinol.
The in-life portion of this trial completed in early 2002 with the full analysis
of the data submitted to a leading peer reviewed journal in late third quarter
2002. This publication was complex and designed to tie together the results of
the clinical trial with the substantial and growing amount of preclinical
scientific data and theory that supports the MPAC technology. It is clear from
the time elapsed that it has not been a simple task to get a paper like this,
with its broad clinical and preclinical conclusions, published. Using the
feedback we have received from editors, we are now in the process of
reformatting the publication for resubmission. What I am excited to tell you is
that multiple major Pharmaceutical companies have rigorously assessed the
clinical results and the MPAC theory and have, in their words "bought into the
science" and remain very interested in entering into a potential deal with
Prana. Our back-up and follow-up chemistry programs are of special interest to
these companies and with almost 300 compounds, they provide any potential
partner with a large selection of compounds with the appropriate attributes for
clinical development. We expect that at least one partnership deal will be
concluded in 2003 and that the potential exists for a further 1 or more
compounds to enter the clinic in 2004.
It is probably appropriate here to spend a few minutes clarifying why "Big
Pharma" finds Prana's MPAC mechanism and portfolio so interesting. Clearly the
problem with present Alzheimer's disease treatments is their inability to
address the underlying cause of the disease. The market leading treatments
appear to provide short-lived symptomatic relief in the form of a temporary
slowing in the decline of patient's cognition. After an initial improvement
patients fall back on a similar decline curve to that seen prior to treatment.
Pranas clinical trial with clioquinol provided an indication that this class of
compound has the potential to provide a much more profound effect - modifying
disease progression, changing the fundamental course of the disease. Whilst it
was very pleasing to show that clioquinol can have a striking and statistically
significant positive effect on cognition in the more severe patients, above and
beyond that of Aricept (Pfizer), it is the observation that an MPAC can
positively affect the levels of beta-amyloid in patients with less severe
disease that raises the possibility of disease modification. So although
receiving less initial press, it is clear to me that it is this later point
which makes Prana's portfolio so sought after and commercial attractive. This
provides the potential for disease modification rather than just temporary
symptom relief. Independent market analysis has put the sales potential for a
true disease modifying agent in Alzheimer's disease above US$10 billion.
Although Prana's most advanced area of research is Alzheimer's disease, there is
a clear and growing body of new evidence (much of which is as yet unpublished)
that the MPAC platform technology has potential in a variety of other serious
diseases. Prana has, at present, preclinical data supporting the applicability
of this technology to other neurological diseases and diseases outside
neurology. Both in-house and collaborative research programs are being pursued
to exploit the broad applicability of the MPAC platform technology.
In addition to this, Prana scientists are also beginning to develop programs for
the long-term treatment of Alzheimer's disease using new proprietary
technologies other than the MPAC platform and also to develop Alzheimer's
disease diagnostics.
Prana's R&D plan for 2003/04 has been designed to optimise the number of uses
for its MPAC technology including the treatment of Alzheimer's and other
diseases, but also to exploit additional discoveries in Alzheimer's treatment
and diagnosis. I believe we are on track to meet our 2003 milestones.
Extract from Vice President of Intellectual Property presentation
The company's portfolio covers multiple mechanisms implicated in the underlying
pathology of Alzheimer's Disease and other neurodegenerative disorders. The
MPAC's are directed to several of these mechanisms.
The recently completed clinical trial with clioquinol validated Prana's work by
showing what MPAC's can do. Prana is the first to recognise the validity of the
MPAC approach and hence to focus its chemistry expertise on developing a body of
understanding of which structures will best demonstrate MPAC activity. The
discovery of which structural components of a compound are responsible for the
desired pharmacological and therapeutic outcomes gives Prana a tremendous lead
in developing valuable Intellectual Property. For example, an understanding of
what influences toxicity, what enhances blood brain penetration and what
attenuates the metal protein interaction etc. Indeed, the discoveries to date
have been captured in 6 new patent families, filed in recent months. The
protection sought in each patent application includes MPAC composition of matter
claims, method of production claims and claims to the utility of the MPACs in
the treatment of numerous neurological disorders.
--------------------------------------------------------------------------------
Page 3 of 26
Appendix 4B
Prana Biotechnology Limited Half yearly report - 31 December 2002
--------------------------------------------------------------------------------
If we look at clioquinol specifically, Prana's preparedness to settle this well
known patent dispute will be heavily influenced by the interests of our future
licensees and their development plans for our MPAC platform.
Our aim is one of continual expansion of our patent portfolio to protect the
growing MPAC technology platform and its application to multiple disease
targets.
Signed in accordance with a resolution of the Board of Directors
/s/Geoffrey Kempler
Geoffrey Kempler
Executive Chairman
Date this 13th day of March 2003
--------------------------------------------------------------------------------
Page 4 of 26
Appendix 4B
Prana Biotechnology Limited Half yearly report - 31 December 2002
--------------------------------------------------------------------------------
Rules 4.1, 4.3
Appendix 4B
Half yearly/preliminary final report
Introduced 30/6/2002.
Name of entity
-------------------------------------------------------------------------------
PRANA BIOTECHNOLOGY LIMITED
-------------------------------------------------------------------------------
ABN or equivalent company Half yearly Preliminary Half year/financial
reference (tick) final (tick) year ended (`current
period')
---------------------------- -------- -------- -----------------
37 080 699 065 X 31 December 2002
---------------------------- -------- -------- -----------------
For announcement to the market
Extracts from this report for announcement to the market (see note 1). $A
-------------------------------------------------------------------------------------------------
Revenues from ordinary activities (item 1.1) down 12% to 526,700
Profit (loss) from ordinary activities after tax attributable up 24% to (3,138,115)
to members (item 1.22)
Profit (loss) from extraordinary items after tax attributable gain (loss)
to members (item 2.5(d)) of
Net profit (loss) for the period attributable to members up 24% to (3,138,115)
(item 1.11)
-------------------------------------------------------------------------------------------------
-----------------------------------------------------------------------------------------------------------
Dividends (distributions) Amount per security Franked amount per
security
-----------------------------------------------------------------------------------------------------------
Final dividend (Preliminary final report only - item 15.4)
Interim dividend (Half yearly report only - item 15.6) -(cent) -(cent)
-----------------------------------------------------------------------------------------------------------
Previous corresponding period (Preliminary final report -
item 15.5; half yearly report - item 15.7) -(cent) -(cent)
-----------------------------------------------------------------------------------------------------------
---------------------
+Record date for determining entitlements to the
dividend, -
(in the case of a trust, distribution) (see item 15.2)
---------------------
Brief explanation of any of the figures reported above (see Note 1) and short
details of any bonus or cash issue or other item(s) of importance not previously
released to the market:
--------------------------------------------------------------------------------
If this is a half yearly report it is to be read in conjunction with the most
recent annual financial report.
--------------------------------------------------------------------------------
Page 5 of 26
Appendix 4B
Prana Biotechnology Limited Half yearly report - 31 December 2002
--------------------------------------------------------------------------------
Condensed consolidated statement of financial performance
-----------------------------------------------
Current period Previous corresponding
$A period
July - Dec 01
$A
-----------------------------------------------
1.1 Revenues from ordinary activities (see items 1.23 526,700 601,089
-1.25)
1.2 Expenses from ordinary activities (see items 1.26 (3,664,815) (3,135,011)
& 1.27)
1.3 Borrowing costs - -
1.4 Share of net profits (losses) of associates and - -
joint venture entities (see item 16.7)
-----------------------------------------------------------------------------------------------------------
1.5 Profit (loss) from ordinary activities before tax (3,138,115) (2,533,922)
1.6 Income tax on ordinary activities (see note 4) - -
-----------------------------------------------------------------------------------------------------------
1.7 Profit (loss) from ordinary activities after tax (3,138,115) (2,533,922)
1.8 Profit (loss) from extraordinary items after tax - -
(see item 2.5)
-----------------------------------------------------------------------------------------------------------
1.9 Net profit (loss) (3,138,115) (2,533,922)
1.10 Net profit (loss) attributable to outside +equity
interests - -
-----------------------------------------------------------------------------------------------------------
1.11 Net profit (loss) for the period attributable to (3,138,115) (2,533,922)
members
-----------------------------------------------------------------------------------------------------------
Non-owner transaction changes in equity
1.12 Increase (decrease) in revaluation reserves - -
1.13 Net exchange differences recognised in equity - -
1.14 Other revenue, expense and initial adjustments
recognised directly in equity (attach details)
Initial adjustments from UIG transitional - -
1.15 provisions - -
-----------------------------------------------------------------------------------------------------------
1.16 Total transactions and adjustments recognised
directly in equity (items 1.12 to 1.15) - -
-----------------------------------------------------------------------------------------------------------
1.17 Total changes in equity not resulting from
transactions with owners as owners (3,138,115) (2,533,922)
-----------------------------------------------------------------------------------------------------------
--------------------------------------------
Current period Previous corresponding
Earnings per security (EPS) period
July - Dec 01
$A
-------------------------------------------------------------------------------
1.18 Basic EPS (5.3 cents) (4.4 cents)
1.19 Diluted EPS (5.3 cents) (4.4 cents)
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
Page 6 of 26
Appendix 4B
Prana Biotechnology Limited Half yearly report - 31 December 2002
--------------------------------------------------------------------------------
Notes to the condensed consolidated statement of financial performance
Profit (loss) from ordinary activities attributable to members
---------------------------------------------
Current period Previous corresponding
$A period
July - Dec 01
$A
----------------------------------------------
1.20 Profit (loss) from ordinary activities after tax (3,138,115) (2,533,922)
(item 1.7)
1.21 Less (plus) outside +equity interests - -
-----------------------------------------------------------------------------------------------------------
1.22 Profit (loss) from ordinary activities after (3,138,115) (2,533,922)
tax, attributable to members
-----------------------------------------------------------------------------------------------------------
Revenue and expenses from ordinary activities
(see note 15)
----------------------------------------------
Current period Previous corresponding
$A period
July - Dec 01
$A
---------------------------------------------
1.23 Revenue from sales or services - -
1.24 Interest revenue 57,483 132,089
1.25 Other relevant revenue - Start Grant 469,217 469,000
-------------------------------------------------------------------------------------------------
526,700 601,089
-------------------------------------------------------------------------------------------------
1.26 Details of relevant expenses
Patents/Research and Development Costs (1,447,215) (1,527,741)
Consulting Fees (382,278) (197,924)
Legal Fees (322,772) (357,458)
Wages (454,866) (270,387)
Corporate Compliance (468,702) (203,365)
Amortisation of Intangibles (550,000) (550,001)
Other - -
------- -------
Total item 1.26 (3,625,833) (3,106,876)
1.27 Depreciation and amortisation excluding (38,982) (28,135)
amortisation of intangibles (see item 2.3)
-------------------------------------------------------------------------------------------------
Total items 1.26 & 1.27 (3,664,815) (3,135,011)
-------------------------------------------------------------------------------------------------
Net Profit (Loss) before tax (Item 1.5) (3,138,115) (2,533,922)
----------------------------------------------------------------------------------------------------------
Capitalised outlays
1.28 Interest costs capitalised in asset values - -
1.29 Outlays capitalised in intangibles (unless - -
arising from an +acquisition of a business)
----------------------------------------------------------------------------------------------------------
Consolidated retained profits
----------------------------------------------
Current period Previous corresponding
$A period
July - Dec 01
$A
----------------------------------------------
1.30 Retained profits (accumulated losses) at the
beginning of the financial period (10,994,424) (5,545,957)
1.31 Net profit (loss) attributable to members (item (3,138,115) (2,533,922)
1.11)
--------------------------------------------------------------------------------
Page 7 of 26
Appendix 4B
Prana Biotechnology Limited Half yearly report - 31 December 2002
--------------------------------------------------------------------------------
1.32 Net transfers from (to) reserves (details if - -
material)
1.33 Net effect of changes in accounting policies - -
1.34 Dividends and other equity distributions paid or - -
payable
-----------------------------------------------------------------------------------------------------------
1.35 Retained profits (accumulated losses) at end of (14,132,539) (8,079,879)
financial period
------------------------------------------------------------------------------------------------------------
Intangible and extraordinary items
------------------------------------------------------------------
Consolidated - current period
------------------------------------------------------------------
Before tax Related tax Related Amount (after
$A $A outside tax)
+equity attributable
interests to members
(a) (b) $A $A
(c) (d)
------------------------------------------------------------------
2.1 Amortisation of goodwill - - - -
2.2 Amortisation of other 550,000 - - 550,000
intangibles
------------------------------------------------------------------
2.3 Total amortisation of
intangibles 550,000 - - 550,000
-----------------------------------------------------------------------------------------------------------
2.4 Extraordinary items (details) - - - -
------------------------------------------------------------------
2.5 Total extraordinary items - - - -
-----------------------------------------------------------------------------------------------------------
--------------------------------------------------
Comparison of half year profits Current year Previous corresponding
(Preliminary final report only) $A period
July - Dec 01
$A
--------------------------------------------------
3.1 Consolidated profit (loss) from ordinary n/a n/a
activities after tax attributable to members
reported for the 1st half year (item 1.22 in
the half yearly report)
--------------------------------------------------
3.2 Consolidated profit (loss) from ordinary n/a n/a
activities after tax attributable to members
for the 2nd half year
--------------------------------------------------
--------------------------------------------------------------------------------
Page 8 of 26
Appendix 4B
Prana Biotechnology Limited Half yearly report - 31 December 2002
--------------------------------------------------------------------------------
-------------------------------------------------------
Condensed consolidated statement of financial At end of As shown in last As in last half
position current period annual report $A yearly report $A
$A
-------------------------------------------------------
Current assets
4.1 Cash 1,446,025 3,585,014 5,508,105
4.2 Receivables 60,929 107,936 5,365
4.3 Investments - 0 0
4.4 Inventories - 0 0
4.5 Tax assets - 0 0
4.6 Other (provide details if material) 50,248 60,367 42,422
-------------------------------------------------------
4.7 Total current assets 1,557,202 3,753,317 5,555,892
------------------------------------------------------------------------------------------------------------
Non-current assets
4.8 Receivables - - -
4.9 Investments (equity accounted) - - -
4.10 Other investments - - -
4.11 Inventories - - -
4.12 Exploration and evaluation expenditure
capitalised (see para .71 of AASB 1022) -
- -
4.13 Development properties (+mining -
entities) - -
4.14 Other property, plant and equipment
(net) 188,483 139,653 159,163
4.15 Intangibles (net) 13,138,349 13,688,349 14,238,351
4.16 Tax assets - - -
4.17 Other (provide details if material) - - -
-------------------------------------------------------
4.18 Total non-current assets 13,326,832 13,828,002 14,397,514
------------------------------------------------------------------------------------------------------------
4.19 Total assets 14,884,034 17,581,319 19,953,406
------------------------------------------------------------------------------------------------------------
Current liabilities
4.20 Payables (1,150,825) (912,333) (1,071,017)
4.21 Interest bearing liabilities - - -
4.22 Tax liabilities - - -
4.23 Provisions exc. tax liabilities - - (23,434)
4.24 Other (provide details if material) - - -
-------------------------------------------------------
4.25 Total current liabilities (1,150,825) (912,333) (1,094,451)
------------------------------------------------------------------------------------------------------------
Non-current liabilities
4.26 Payables - - -
4.27 Interest bearing liabilities - - -
4.28 Tax liabilities - - -
4.29 Provisions exc. tax liabilities - - -
4.30 Other (provide details if material) - - -
-------------------------------------------------------
4.31 Total non-current liabilities - - -
-------------------------------------------------------
--------------------------------------------------------------------------------
Page 9 of 26
Appendix 4B
Prana Biotechnology Limited Half yearly report - 31 December 2002
--------------------------------------------------------------------------------
Condensed consolidated statement of financial position continued
------------------------------------------------------------------------------------------------------------
4.32 Total liabilities (1,150,825) (912,333) (1,094,451)
------------------------------------------------------------------------------------------------------------
4.33 Net assets 13,733,209 16,668,986 18,858,955
------------------------------------------------------------------------------------------------------------
-------------------------------------------------------
Equity
4.34 Capital/contributed equity 13,203,806 13,001,468 12,276,893
4.35 Reserves 14,661,942 14,661,942 14,661,942
4.36 Retained profits (accumulated losses) (14,132,539) (10,994,424) (8,079,880)
------------------------------------------------------------------------------------------------------------
4.37 Equity attributable to members of the
parent entity 13,733,209 16,668,986 18,858,955
4.38 Outside +equity interests in controlled - - -
entities
-------------------------------------------------------
4.39 Total equity 13,733,209 16,668,986 18,858,955
------------------------------------------------------------------------------------------------------------
-------------------------------------------------------
4.40 Preference capital included as part of - - -
4.37
------------------------------------------------------------------------------------------------------------
Notes to the condensed consolidated statement of financial position
Exploration and evaluation expenditure capitalised
(To be completed only by entities with mining interests if amounts are material.
Include all expenditure incurred.)
-----------------------------------------
Current period Previous
$A corresponding period
July - Dec 01
$A
-----------------------------------------
5.1 Opening balance - -
5.2 Expenditure incurred during current period - -
5.3 Expenditure written off during current period - -
5.4 Acquisitions, disposals, revaluation increments, - -
etc.
5.5 Expenditure transferred to Development Properties - -
-----------------------------------------
5.6 Closing balance as shown in the consolidated - -
balance sheet (item 4.12)
-------------------------------------------------------------------------------------------------------
Development properties
(To be completed only by entities with mining interests if amounts are material)
----------------------------------------------
Current period Previous
$A corresponding period
July - Dec 01
$A
----------------------------------------------
6.1 Opening balance - -
6.2 Expenditure incurred during current period - -
6.3 Expenditure transferred from exploration and - -
evaluation
6.4 Expenditure written off during current period - -
6.5 Acquisitions, disposals, revaluation increments, - -
etc.
6.6 Expenditure transferred to mine properties - -
----------------------------------------------
6.7 Closing balance as shown in the consolidated - -
balance sheet (item 4.13)
----------------------------------------------
--------------------------------------------------------------------------------
Page 10 of 26
Appendix 4B
Prana Biotechnology Limited Half yearly report - 31 December 2002
--------------------------------------------------------------------------------
Condensed consolidated statement of cash flows
------------------------------------------------
Current period Previous
$A corresponding period
July - Dec 01
$A
------------------------------------------------
Cash flows related to operating activities
7.1 Receipts from customers - -
7.2 Payments to suppliers and employees (2,725,319) (2,134,117)
7.3 Dividends received from associates - -
7.4 Other dividends received - -
7.5 Interest and other items of similar nature
received 57,483 163,634
7.6 Interest and other costs of finance paid - -
7.7 Income taxes paid - -
7.8 Other - Start Grant 467,945 695,000
------------------------------------------------
7.9 Net operating cash flows (2,199,891) (1,275,483)
--------------------------------------------------------------------------------------------------------
Cash flows related to investing activities
7.10 Payment for purchases of property, plant and
equipment (87,812) (71,285)
7.11 Proceeds from sale of property, plant and
equipment - -
7.12 Payment for purchases of equity investments - -
7.13 Proceeds from sale of equity investments - -
7.14 Loans to other entities - -
7.15 Loans repaid by other entities - -
7.16 Other (provide details if material) - -
------------------------------------------------
7.17 Net investing cash flows (87,812) (71,285)
--------------------------------------------------------------------------------------------------------
Cash flows related to financing activities
7.18 Proceeds from issues of +securities (shares,
options, etc.) 148,714 -
7.19 Proceeds from borrowings - -
7.20 Repayment of borrowings - -
7.21 Dividends paid - -
7.22 Other (provide details if material) - -
------------------------------------------------
7.23 Net financing cash flows 148,714 -
--------------------------------------------------------------------------------------------------------
7.24 Net increase (decrease) in cash held (2,138,989) (1,346,768)
7.25 Cash at beginning of period 3,585,014 6,854,873
(see Reconciliation of cash)
7.26 Exchange rate adjustments to item 7.25. - -
------------------------------------------------
7.27 Cash at end of period 1,446,025 5,508,105
(see Reconciliation of cash)
------------------------------------------------
Non-cash financing and investing activities
Details of financing and investing transactions which have had a material effect
on consolidated assets and liabilities but did not involve cash flows are as
follows. ( If an amount is quantified, show comparative amount.)
----------------------------------------------------------------------
----------------------------------------------------------------------
--------------------------------------------------------------------------------
Page 11 of 26
Appendix 4B
Prana Biotechnology Limited Half yearly report - 31 December 2002
--------------------------------------------------------------------------------
Reconciliation of cash
-----------------------------------------------
Reconciliation of cash at the end of the period (as shown Current period Previous
in the consolidated statement of cash flows) to the related $A corresponding period
items in the accounts is as follows. July - Dec 01
$A
-------------------------------------------------------------------------------------------------------------
8.1 Cash on hand and at bank 1,446,025 5,508,105
8.2 Deposits at call - -
8.3 Bank overdraft - -
8.4 Other (provide details) - -
------------------------------------------
8.5 Total cash at end of period (item 7.27) 1,446,025 5,508,105
--------------------------------------------------------------------------------------------------------
Other notes to the condensed financial statements
---------------------------------------------
Ratios Current period Previous
$A corresponding period
July - Dec 01
$A
---------------------------------------------
Profit before tax / revenue
9.1 Consolidated profit (loss) from ordinary activities (595.81%) (421.55%)
before tax (item 1.5) as a percentage of revenue
(item 1.1)
---------------------------------------------------------------------------------------------------------
Profit after tax / +equity interests
9.2 Consolidated net profit (loss) from ordinary (22.85%) (13.44%)
activities after tax attributable to members (item
1.11) as a percentage of equity (similarly
attributable) at the end of the period (item 4.37)
------------------------------------------------------------------------------------------------------------
--------------------------------------------------------------------------------
Page 12 of 26
Appendix 4B
Prana Biotechnology Limited Half yearly report - 31 December 2002
--------------------------------------------------------------------------------
Earnings per security (EPS)
10. Details of basic and diluted EPS reported separately in accordance with
paragraph 9 and 18 of AASB 1027: Earnings Per Share are as follows.
--------------------------------------------------------------------------------
Basic Earnings per share (5.34 cents)
------------------------
(Item 1.18)
Net Loss for period (Item 1.1) 3,138,115
Weighted Average Number of ordinary Shares = 58,721,755
Diluted Earnings per share
--------------------------
Diluted Earnings per Share is the same as Basic earnings per share as the
dilutive options have not increased the loss per share.
--------------------------------------------------------------------------------
---------------------------------------
NTA backing Current period Previous corresponding
(see note 7) $A period
July - Dec 01
$A
-------------------------------------------------------------------------------
11.1 Net tangible asset backing
per +ordinary security $0.010 $0.0810
---------------------------------------
Discontinuing Operations
(Entities must report a description of any significant activities or events
relating to discontinuing operations in accordance with paragraph 7.5 (g) of
AASB 1029: Interim Financial Reporting, or, the details of discontinuing
operations they have disclosed in their accounts in accordance with AASB 1042:
Discontinuing Operations (see note 17).)
12.1 Discontinuing Operations
--------------------------------------------------------------------------------
Not applicable
--------------------------------------------------------------------------------
Control gained over entities having material effect
-----------------------------------
13.1 Name of entity (or group of Not applicable
entities)
-----------------------------------
-------------
13.2 Consolidated profit (loss) from ordinary activities and
extraordinary items after tax of the controlled entity
(or group of entities) since the date in the current $
period on which control was +acquired
-------------
13.3 Date from which such profit has been calculated
-------------
13.4 Profit (loss) from ordinary activities and
extraordinary items after tax of the controlled entity
(or group of entities) for the whole of the previous $
corresponding period
-------------
--------------------------------------------------------------------------------
Page 13 of 26
Appendix 4B
Prana Biotechnology Limited Half yearly report - 31 December 2002
--------------------------------------------------------------------------------
Loss of control of entities having material effect
-----------------------------
14.1 Name of entity (or group of entities) Not applicable
-----------------------------
---------
14.2 Consolidated profit (loss) from ordinary activities and
extraordinary items after tax of the controlled entity
(or group of entities) for the current period to the $
date of loss of control
---------
14.3 Date to which the profit (loss) in item 14.2 has been
calculated
---------
14.4 Consolidated profit (loss) from ordinary activities and
extraordinary items after tax of the controlled entity
(or group of entities) while controlled during the $
whole of the previous corresponding period
---------
14.5 Contribution to consolidated profit (loss) from
ordinary activities and extraordinary items from sale
of interest leading to loss of control $
---------
Dividends (in the case of a trust, distributions)
--------------
15.1 Date the dividend (distribution) is payable Not applicable
--------------
--------------
15.2 +Record date to determine entitlements to the dividend
(distribution) (ie, on the basis of proper instruments
of transfer received by 5.00 pm if +securities are not
+CHESS approved, or security holding balances
established by 5.00 pm or such later time permitted by
SCH Business Rules if +securities are +CHESS approved)
--------------
--------------
15.3 If it is a final dividend, has it been declared?
(Preliminary final report only)
--------------
Amount per security
----------------------------------------------------------------------------------------------------------------
Amount per Franked amount Amount per
security per security security of
at % tax foreign source
(see note 4) dividend
----------------------------------------------------------------------------------------------------------------
(Preliminary final report only)
15.4 Final dividend: Current year -(cent) -(cent) -(cent)
15.5 Previous year -(cent) -(cent) -(cent)
----------------------------------------------------------------------------------------------------------------
(Half yearly and preliminary final reports)
15.6 Interim dividend: Current year -(cent) -(cent) -(cent)
15.7 Previous year -(cent) -(cent) -(cent)
----------------------------------------------------------------------------------------------------------------
--------------------------------------------------------------------------------
Page 14 of 26
Appendix 4B
Prana Biotechnology Limited Half yearly report - 31 December 2002
--------------------------------------------------------------------------------
Total dividend (distribution) per security (interim plus final)
(Preliminary final report only)
----------------------------
Current year Previous year
----------------------------
15.8 +Ordinary securities n/a n/a
15.9 Preference +securities n/a n/a
----------------------------
Half yearly report - interim dividend (distribution) on all securities or
Preliminary final report - final dividend (distribution) on all securities
------------------------------
Current period Previous
$A corresponding
period
July - Dec 01
$A
------------------------------
15.10 +Ordinary securities
(each class separately) - -
15.11 Preference +securities (each class - -
separately)
15.12 Other equity instruments (each class - -
separately)
------------------------------
- -
15.13 Total
------------------------------
The +dividend or distribution plans shown below are in operation.
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
---------------
The last date(s) for receipt of election notices for the
+dividend or distribution plans
---------------
Any other disclosures in relation to dividends (distributions). (For half yearly
reports, provide details in accordance with paragraph 7.5(d) of AASB 1029
Interim Financial Reporting)
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
Details of aggregate share of profits (losses) of associates and joint venture entities
------------------------------
Current period Previous
Group's share of associates' and joint $A corresponding
venture entities': period
July - Dec 01
$A
------------------------------
16.1 Profit (loss) from ordinary activities before tax - -
16.2 Income tax on ordinary activities - -
------------------------------
16.3 Profit (loss) from ordinary activities after tax - -
16.4 Extraordinary items net of tax - -
------------------------------
16.5 Net profit (loss) - -
16.6 Adjustments - -
------------------------------
16.7 Share of net profit (loss) of associates and - -
joint venture entities
------------------------------
--------------------------------------------------------------------------------
Page 15 of 26
Appendix 4B
Prana Biotechnology Limited Half yearly report - 31 December 2002
--------------------------------------------------------------------------------
Material interests in entities which are not controlled entities
The economic entity has an interest (that is material to it) in the following
entities. (If the interest was acquired or disposed of during either the current
or previous corresponding period, indicate date of acquisition ("from dd/mm/yy")
or disposal ("to dd/mm/yy").)
------------------------------------------------------------------------------
Name of entity Percentage of ownership interest Contribution to net profit (loss)
held at end of period or date of (item 1.9)
disposal
-------------------------------------------------------------------------------------------------------------
Current Previous Current period Previous
Period corresponding $A corresponding
period period
July - Dec 01
$A
------------------------------------------------------------------------------
17.1 Equity accounted n/a 0% n/a 0
associates and joint
venture entities
------------------------------------------------------------------------------------------------------------
17.2 Total n/a 0% n/a 0
------------------------------------------------------------------------------------------------------------
17.3 Other material n/a 0% n/a 0
interests
------------------------------------------------------------------------------------------------------------
17.4 Total n/a 0% n/a 0
------------------------------------------------------------------------------------------------------------
--------------------------------------------------------------------------------
Page 16 of 26
Appendix 4B
Prana Biotechnology Limited Half yearly report - 31 December 2002
--------------------------------------------------------------------------------
Issued and quoted securities at end of current period
(Description must include rate of interest and any redemption or conversion
rights together with prices and dates)
------------------------------------------------------------------
Issue price Amount paid
Category of +securities Total number Number quoted per security up per
(see note 14) security
(cents) (see
note
14)
(cents)
------------------------------------------------------------------
18.1 Preference +securities - -
(description)
------------------------------------------------------------------
18.2 Changes during current period
(a) Increases through issues
(b) Decreases through returns
of capital, buybacks,
redemptions
--------------------------------------------------------------------------------------------------------------
18.3 +Ordinary securities 58,939,045 58,939,045
------------------------------------------------------------------
18.4 Changes during current period
(a) Increases through issues 326,295 326,295
(b) Decreases through returns -
of capital, buybacks
--------------------------------------------------------------------------------------------------------------
18.5 +Convertible debt securities -
(description and conversion
factor)
------------------------------------------------------------------
18.6 Changes during current period
(a) Increases through issues
(b) Decreases through securities
matured, converted
--------------------------------------------------------------------------------------------------------------
18.7 Options (description and Exercise Expiry
conversion factor) price date
(if any)
------------------------------
PBTO 7,000,157 7,000,157 $0.50 01/03/03
PBTAK 20,200,000 - $0.50 01/12/04
PBTAM 200,000 - $0.50 01/03/04
PBTAO 410,000 - $0.50 30/06/05
PBTAQ 200,000 - $0.50 01/10/05
------------------------------------------------------------------
28,010,157 7,000,157
------------------------------------------------------------------
18.8 Issued during current period 413,274
------------------------------------------------------------------
18.9 Exercised during current period 297,427
------------------------------------------------------------------
18.10 Expired during current period - -
--------------------------------------------------------------------------------------------------------------
-
18.11 Debentures (description)
18.12 Changes during current period
(a) Increases through issues
(b) Decreases through securities
matured, converted
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
Page 17 of 26
Appendix 4B
Prana Biotechnology Limited Half yearly report - 31 December 2002
--------------------------------------------------------------------------------
-------------------------------------------------------------------------------
18.13 Unsecured notes (description) -
Changes during current period
18.14
(a) Increases through issues
(b) Decreases through securities matured, converted
-------------------------------------------------------------------------------
Segment reporting
(Information on the business and geographical segments of the entity must be
reported for the current period in accordance with AASB 1005: Segment Reporting
and for half year reports, AASB 1029: Interim Financial Reporting. Because
entities employ different structures a pro forma cannot be provided. Segment
information in the layout employed in the entity's +accounts should be reported
separately and attached to this report.)
The Company's activities are predominantly within Australia and cover research
into Alzheimer's Disease and other major age-related degenerative disorders.
Comments by directors
(Comments on the following matters are required by ASX or, in relation to the
half yearly report, by AASB 1029: Interim Financial Reporting. The comments do
not take the place of the directors' report and statement (as required by the
Corporations Act) and may be incorporated into the directors' report and
statement. For both half yearly and preliminary final reports, if there are no
comments in a section, state NIL. If there is insufficient space to comment,
attach notes to this report.)
Basis of financial report preparation
19.1 If this report is a half yearly report, it is a general purpose financial
report prepared in accordance with the listing rules and AASB 1029: Interim
Financial Reporting. It should be read in conjunction with the last +annual
report and any announcements to the market made by the entity during the
period. The financial statements in this report are "condensed financial
statements" as defined in AASB 1029: Interim Financial Reporting. This
report does not include all the notes of the type normally included in an
annual financial report. [Delete if preliminary final report.]
19.2 Material factors affecting the revenues and expenses of the economic entity
for the current period. In a half yearly report, provide explanatory
comments about any seasonal or irregular factors affecting operations.
-------------------------------------------------------------------
Nil
-------------------------------------------------------------------
19.3 A description of each event since the end of the current period which has
had a material effect and which is not already reported elsewhere in this
Appendix or in attachments, with financial effect quantified (if possible).
--------------------------------------------------------------------
Nil
--------------------------------------------------------------------
19.4 Franking credits available and prospects for paying fully or partly franked
dividends for at least the next year.
--------------------------------------------------------------------------------
Page 18 of 26
Appendix 4B
Prana Biotechnology Limited Half yearly report - 31 December 2002
--------------------------------------------------------------------------------
-------------------------------------------------------------------------------
nil
-------------------------------------------------------------------------------
19.5 Unless disclosed below, the accounting policies, estimation methods and
measurement bases used in this report are the same as those used in the
last annual report. Any changes in accounting policies, estimation methods
and measurement bases since the last annual report are disclosed as
follows. (Disclose changes and differences in the half yearly report in
accordance with AASB 1029: Interim Financial Reporting. Disclose changes in
accounting policies in the preliminary final report in accordance with AASB
1001: Accounting Policies-Disclosure).
--------------------------------------------------------------------------------
-
--------------------------------------------------------------------------------
19.6 Revisions in estimates of amounts reported in previous interim periods. For
half yearly reports the nature and amount of revisions in estimates of
amounts reported in previous +annual reports if those revisions have a
material effect in this half year.
--------------------------------------------------------------------------------
-
--------------------------------------------------------------------------------
19.7 Changes in contingent liabilities or assets. For half yearly reports,
changes in contingent liabilities and contingent assets since the last +
annual report.
--------------------------------------------------------------------------------
There has been no change in the status of the matter of P.N. Gerolymatos since
the last annual report other than that disclosed in public announcements on the
ASX.
--------------------------------------------------------------------------------
Additional disclosure for trusts
--------------
20.1 Number of units held by the management company
or responsible entity or their related parties. Not applicable
--------------
--------------
20.2 A statement of the fees and commissions payable
to them anagement company or responsible entity.
Identify:
- initial service charges
- management fees
- other fees
--------------
--------------------------------------------------------------------------------
Page 19 of 26
Appendix 4B
Prana Biotechnology Limited Half yearly report - 31 December 2002
--------------------------------------------------------------------------------
Annual meeting
(Preliminary final report only)
The annual meeting will be held as follows:
---------------------
Place n/a
---------------------
Date
---------------------
Time
---------------------
Approximate date the +annual report will be available
---------------------
Compliance statement
1 This report has been prepared in accordance with AASB Standards, other AASB
authoritative pronouncements and Urgent Issues Group Consensus Views or
other standards acceptable to ASX (see note 12).
---------------------------------
Identify other standards used n/a
---------------------------------
2 This report, and the +accounts upon which the report is based (if
separate), use the same accounting policies.
3 This report does give a true and fair view of the matters disclosed (see
note 2).
4 This report is based on +accounts to which one of the following applies.
(Tick one)
The +accounts have been audited. X The +accounts have been subject
to review.
The +accounts are in the The +accounts have not yet been
process of being audited or audited or reviewed.
subject to review.
5 If the audit report or review by the auditor is not attached, details of
any qualifications are attached.
6 The entity has a formally constituted audit committee.
Sign here: /s/Geoffrey Kempler Date: 13 March 2003
Director
Print name: Geoffrey Kempler
--------------------------------------------------------------------------------
Page 20 of 26
Appendix 4B
Prana Biotechnology Limited Half yearly report - 31 December 2002
--------------------------------------------------------------------------------
Notes
1. For announcement to the market The percentage changes referred to in this
section are the percentage changes calculated by comparing the current
period's figures with those for the previous corresponding period. Do not
show percentage changes if the change is from profit to loss or loss to
profit, but still show whether the change was up or down. If changes in
accounting policies or procedures have had a material effect on reported
figures, do not show either directional or percentage changes in profits.
Explain the reason for the omissions in the note at the end of the
announcement section. Entities are encouraged to attach notes or fuller
explanations of any significant changes to any of the items in page 1. The
area at the end of the announcement section can be used to provide a cross
reference to any such attachment.
2. True and fair view If this report does not give a true and fair view of a
matter (for example, because compliance with an Accounting Standard is
required) the entity must attach a note providing additional information
and explanations to give a true and fair view.
3. Condensed consolidated statement of financial performance
Item 1.1 The definition of "revenue" and an explanation of "ordinary
activities" are set out in AASB 1004: Revenue, and AASB 1018:
Statement of Financial Performance.
Item 1.6 This item refers to the total tax attributable to the amount
shown in item 1.5. Tax includes income tax and capital gains tax
(if any) but excludes taxes treated as expenses from ordinary
activities (eg, fringe benefits tax).
4. Income tax If the amount provided for income tax in this report differs (or
would differ but for compensatory items) by more than 15% from the amount
of income tax prima facie payable on the profit before tax, the entity must
explain in a note the major items responsible for the difference and their
amounts. The rate of tax applicable to the franking amount per dividend
should be inserted in the heading for the column "Franked amount per
security at % tax" for items 15.4 to 15.7.
5. Condensed consolidated statement of financial position
Format The format of the consolidated statement of financial position
should be followed as closely as possible. However, additional items may be
added if greater clarity of exposition will be achieved, provided the
disclosure still meets the requirements of AASB 1029: Interim Financial
Reporting, and AASB 1040: Statement of Financial Position. Also, banking
institutions, trusts and financial institutions may substitute a clear
liquidity ranking for the Current/Non-Current classification.
Basis of revaluation If there has been a material revaluation of
non-current assets (including investments) since the last +annual report,
the entity must describe the basis of revaluation adopted. The description
must meet the requirements of AASB 1010: Accounting for the Revaluation of
Non-Current Assets. If the entity has adopted a procedure of regular
revaluation, the basis for which has been disclosed and has not changed, no
additional disclosure is required.
6. Condensed consolidated statement of cash flows For definitions of "cash"
and other terms used in this report see AASB 1026: Statement of Cash Flows.
Entities should follow the form as closely as possible, but variations are
permitted if the directors (in the case of a trust, the management company)
believe that this presentation is inappropriate. However, the presentation
adopted must meet the requirements of AASB 1026. +Mining exploration
entities may use the form of cash flow statement in Appendix 5B.
--------------------------------------------------------------------------------
Page 21 of 26
Appendix 4B
Prana Biotechnology Limited Half yearly report - 31 December 2002
--------------------------------------------------------------------------------
7. Net tangible asset backing Net tangible assets are determined by deducting
from total tangible assets all claims on those assets ranking ahead of the
+ordinary securities (ie, all liabilities, preference shares, outside
+equity interests etc). +Mining entities are not required to state a net
tangible asset backing per +ordinary security.
8. Gain and loss of control over entities The gain or loss must be disclosed
if it has a material effect on the +accounts. Details must include the
contribution for each gain or loss that increased or decreased the entity's
consolidated profit (loss) from ordinary activities and extraordinary items
after tax by more than 5% compared to the previous corresponding period.
9. Rounding of figures This report anticipates that the information required
is given to the nearest $1,000. If an entity reports exact figures, the $A
headings must be amended. If an entity qualifies under ASIC Class Order
98/0100 dated 10 July 1998, it may report to the nearest million dollars,
or to the nearest $100,000, and the $A headings must be amended.
10. Comparative figures Comparative figures are to be presented in accordance
with AASB 1018 or AASB 1029 Interim Financial Reporting as appropriate and
are the unadjusted figures from the latest annual or half year report as
appropriate. However, if an adjustment has been made in accordance with an
accounting standard or other reason or if there is a lack of comparability,
a note explaining the position should be attached. For the statement of
financial performance, AASB 1029 Interim Financial Reporting requires
information on a year to date basis in addition to the current interim
period. Normally an Appendix 4B to which AASB 1029 Interim Financial
Reporting applies would be for the half year and consequently the
information in the current period is also the year to date. If an Appendix
4B Half yearly version is produced for an additional interim period (eg
because of a change of reporting period), the entity must provide the year
to date information and comparatives required by AASB 1029 Interim
Financial Reporting. This should be in the form of a multi-column version
of the consolidated statement of financial performance as an attachment to
the additional Appendix 4B.
11. Additional information An entity may disclose additional information about
any matter, and must do so if the information is material to an
understanding of the reports. The information may be an expansion of the
material contained in this report, or contained in a note attached to the
report. The requirement under the listing rules for an entity to complete
this report does not prevent the entity issuing reports more frequently.
Additional material lodged with the +ASIC under the Corporations Act must
also be given to ASX. For example, a director's report and declaration, if
lodged with the +ASIC, must be given to ASX.
12. Accounting Standards ASX will accept, for example, the use of International
Accounting Standards for foreign entities. If the standards used do not
address a topic, the Australian standard on that topic (if one exists) must
be complied with.
13. Corporations Act financial statements This report may be able to be used by
an entity required to comply with the Corporations Act as part of its
half-year financial statements if prepared in accordance with Australian
Accounting Standards.
14. Issued and quoted securities The issue price and amount paid up is not
required in items 18.1 and 18.3 for fully paid securities.
15 Details of expenses AASB 1018 requires disclosure of expenses from ordinary
activities according to either their nature or function. For foreign
entities, there are similar requirements in other accounting standards
accepted by ASX. AASB ED 105 clarifies that the disclosures required by
AASB 1018 must be either all according to nature or all according to
function.
--------------------------------------------------------------------------------
Page 22 of 26
Appendix 4B
Prana Biotechnology Limited Half yearly report - 31 December 2002
--------------------------------------------------------------------------------
Entities must disclose details of expenses using the layout (by nature or
function) employed in their +accounts.
The information in lines 1.23 to 1.27 may be provided in an attachment to
Appendix 4B.
Relevant Items AASB 1018 requires the separate disclosure of specific
revenues and expenses which are not extraordinary but which are of a size,
nature or incidence that disclosure is relevant in explaining the financial
performance of the reporting entity. The term "relevance" is defined in
AASB 1018. There is an equivalent requirement in AASB 1029: Interim
Financial Reporting. For foreign entities, there are similar requirements
in other accounting standards accepted by ASX.
16 Dollars If reporting is not in A$, all references to $A must be changed to
the reporting currency. If reporting is not in thousands of dollars, all
references to "000" must be changed to the reporting value.
17. Discontinuing operations
Half yearly report
All entities must provide the information required in paragraph 12 for half
years beginning on or after 1 July 2001.
Preliminary final report
Entities must either provide a description of any significant activities or
events relating to discontinuing operations equivalent to that required by
paragraph 7.5 (g) of AASB 1029: Interim Financial Reporting, or, the
details of discontinuing operations they are required to disclose in their
+accounts in accordance with AASB 1042 Discontinuing Operations.
In any case the information may be provided as an attachment to this
Appendix 4B.
18. Format
This form is a Word document but an entity can re-format the document into
Excel or similar applications for submission to the Companies Announcements
Office in ASX.
19. Changes in Accounting Standards
The following changes have occurred in Accounting Standards since 1 July
2002 and these changes have been adopted where appropriate in preparation
of this report:
- SB 1012 - Foreign Currency Translation
- SB 1028 - Employee Benefits
- SB 1044 - Provisions, Contingent Liabilities and Contingent Assets
--------------------------------------------------------------------------------
Page 23 of 26
Appendix 4B
Prana Biotechnology Limited Half yearly report - 31 December 2002
--------------------------------------------------------------------------------
20. Income Tax Note
--------------------------------------------------------------------
Dec 2002 Dec 2001
--------------------------------------------------------------------
Prima facie income tax on the operating 941,434 760,177
loss before income tax at 30%
--------------------------------------------------------------------
Non-Tax Deductible Items
- Amortisation of Intangibles (165,000) (165,000)
--------------------------------------------------------------------
Timing differences and tax losses not
brought to account as future income tax
benefits 776,434 595,177
--------------------------------------------------------------------
Income Tax Expense - -
--------------------------------------------------------------------
--------------------------------------------------------------------------------
Page 24 of 26
Appendix 4B
Prana Biotechnology Limited Half yearly report - 31 December 2002
--------------------------------------------------------------------------------
PRANA BIOTECHNOLOGY LIMITED
ABN 37 080 699 065
INTERIM FINANCIAL REPORT
DIRECTORS' DECLARATION
31 December 2002
The directors of the company declare that:
1. The financial statements and notes, as set out on pages 5 to 24:
a. Comply with Accounting Standards AASB 1029: Interim Financial
Reporting and the Corporations Regulations 2001; and
b. Give a true and fair view of the company's financial position as
at 31 December 2002 and of its performance for the half-year
ended on that date.
2. In the directors' opinion there are reasonable grounds to believe that
the company will be able to pay its debts as and when they become due
and payable.
This declaration is made in accordance with a resolution of the Board of
Directors.
Director /s/Geoffrey Kempler
Geoffrey Kempler
Dated this 13th day of March 2003
--------------------------------------------------------------------------------
Page 25 of 25
Appendix 4B
Prana Biotechnology Limited Half yearly report - 31 December 2002
--------------------------------------------------------------------------------
AUDITOR REPORT
Deloitte Touche Tohmatsu
A.B.N. 74 490 121 060 505 Bourke Street
Melbourne VIC 3000 Deloitte
GPO Box 78B Touche
Melbourne VIC 300T Australia Tohmatsu
DX 111
Telephone (03) 9208 7000
Facsimile (03) 9208 7001
www.deloitte.com.au
INDEPENDENT REVIEW REPORT TO THE MEMBERS
OF PRANA BIOTECHNOLOGY LIMITED
Scope
-----
We have reviewed the attached financial report of Prana Biotechnology Limited in
the form of Appendix 4B of the Australian Stock Exchange (ASX) Listing Rules as
set out on pages 5 to 27, including the directors' declaration, for the
half-year ended 31 December 2002, but excluding the following sections:
a) material factors affecting the revenues and expenses of the entity for
the current period (page 16); and
b) compliance statement (page 20).
The disclosing entity's directors are responsible for the financial report. We
have performed an independent review of the financial report in order to state
whether, on the basis of the procedures described, anything has come to our
attention that would indicate that the financial report is not presented fairly
in accordance with Accounting Standard AASB 1029 "Interim Financial Reporting"
and other mandatory professional reporting requirements in Australia, statutory
requirements and ASX Listing Rules as they relate to Appendix 4B, so as to
present a view which is consistent with our understanding of the disclosing
entity's financial position, and performance as represented by the results of
its operations and its cash flows, and in order for the disclosing entity to
meet its obligations to lodge the financial report with the Australian
Securities and Investments Commission and the ASX.
Our review has been conducted in acordance with Australian Auditing Standards
applicable to review engagements. A review is limited primarily to inquiries of
the entity's personnel and analytical procedures applied to the financial data.
These procedures do not provide all the evidence that would be required in an
audit, thus the level of assurance provided is less than given in an audit. We
have not performed an audit and, accordingly, we do not express an audit
opinion.
Statement
---------
Based on our review, which is not an audit, we have not become aware of any
matter that makes us believe that the half-year financial report of Prana
Biotechnology Limited is not in accordance with:
(a) the Corporations Act 2001, including:
(i) giving a true and fair view of the disclosing entity's financial
position as at 31 December 2002 and of its performance for the
half-year ended on that date; and
(ii) complying with Accounting Standard AASB 1029 "Interim Financial
Reporting" and the Corporations Regulations 2001; and
(b) other mandatory professional reporting requirements in Australia and
ASX Listing Rules as they relate to Appendix 4B.
/s/Deloitte Touche Tohmatsu
Deloitte Touche Tohmatsu
/s/C J Biermann
C J Biermann
Partner
Chartered Accountants
Melbourne, 13 March 2003
------------------------------------------------------------
The liability of Deloitte Touche Tohmatsu is limited by, and
to the extent of, the Accountants' Scheme under the
Professional Standards Act 1994 (NSW).
--------------------------------------------------------------------------------
Page 26 of 26
ITEM 2
Appendix 3B
New issue announcement
--------------------------------------------------------------------------------
Rule 2.7, 3.10.3, 3.10.4, 3.10.5
Appendix 3B
New issue announcement,
application for quotation of additional securities
and agreement
Information or documents not available now must be given to ASX as soon as
available. Information and documents given to ASX become ASX's property and may
be made public.
Introduced 1/7/96. Origin: Appendix 5. Amended 1/7/98, 1/9/99, 1/7/2000,
30/9/2001, 11/3/2002, 1/1/2003.
Name of entity
-------------------------------------------------------------------------------
PRANA BIOTECHNOLOGY LIMITED
-------------------------------------------------------------------------------
ABN
----------------------------
37 080 699 065
----------------------------
We (the entity) give ASX the following information.
Part 1 - All issues
You must complete the relevant sections (attach sheets if there is not enough
space).
1 +Class of +securities issued or to be -------------------------------
issued Ordinary Shares
-------------------------------
2 Number of +securities issued or to --------------------------------
be issued (if known) or maximum 3,132,391
number which may be issued --------------------------------
3 Principal terms of the +securities (eg, -------------------------------
if options, exercise price and expiry Pari passu with existing quoted
date; if partly paid +securities, the ordinary shares
amount outstanding and due dates for --------------------------------
payment; if +convertible securities,
the conversion price and dates for
conversion)
--------------------------------------------------------------------------------
+ See chapter 19 for defined terms.
1/1/2003 Appendix 3B Page 1
Appendix 3B
New issue announcement
--------------------------------------------------------------------------------
4 Do the +securities rank equally in all -------------------------------
respects from the date of allotment Yes
with an existing +class of quoted -------------------------------
+securities?
If the additional securities do not
rank equally, please state:
- the date from which they do
- the extent to which they
participate for the next dividend,
(in the case of a trust,
distribution) or interest payment
- the extent to which
they do not rank equally, other than in relation
to the next dividend,
distribution or interest payment
5 Issue price or consideration -------------------------------
$0.50 per share
-------------------------------
6 Purpose of the issue -------------------------------
(If issued as consideration for the Exercise of Options
acquisition of assets, clearly identify
those assets) To be used for Working Capital
Purposes
-------------------------------
7 Dates of entering +securities into -------------------------------
uncertificated holdings or 15/3/03
despatch of certificates -------------------------------
--------------- ---------------
8 Number and +class of all +securities Number +Class
quoted on ASX (including the --------------- ----------------
securities in clause 2 if applicable) 65,765,989(PBT) Ordinary Shares
336,314(PBTN) Options exercisable
at $0.50 on or
before 1 March 2003
--------------- --------------------
--------------------------------------------------------------------------------
+ See chapter 19 for defined terms.
Appendix 3B Page 2 1/1/2003
Appendix 3B
New issue announcement
--------------------------------------------------------------------------------
----------------------------- -------------------------
Number +Class
----------------------------- -------------------------
9 Number and +class of all +securities 20,125,000 (PBTAK) Options exercisable
not quoted on ASX (including the at $0.50 on or
securities in clause 2 if applicable) before 1 December
2004.
200,000 (PBTAM) Options exercisable
at $0.50 on or before
20 March 2004.
Employee &
410,000 (PBTAO) Consultants Options
exercisable at $0.50
on or before 30 June
2005.
200,000 (PBTAQ) Options exercisable
at $0.50 on or
before 1 October
2005.
----------------------------- --------------------------
10 Dividend policy (in the case of a -------------------------------
trust, distribution policy) on the Unchanged
increased capital (interests) -------------------------------
Part 2 - Bonus issue or pro rata issue
11 Is security holder approval -------------------------------
required?
-------------------------------
12 Is the issue renounceable or non- -------------------------------
renounceable?
-------------------------------
13 Ratio in which the +securities will be -------------------------------
offered
-------------------------------
14 +Class of +securities to which the -------------------------------
offer relates
-------------------------------
15 +Record date to determine -------------------------------
entitlements
16 Will holdings on different registers -------------------------------
(or subregisters) be aggregated for
calculating entitlements?
-------------------------------
17 Policy for deciding entitlements in -------------------------------
relation to fractions
-------------------------------
--------------------------------------------------------------------------------
+ See chapter 19 for defined terms.
1/1/2003 Appendix 3B Page 3
Appendix 3B
New issue announcement
--------------------------------------------------------------------------------
18 Names of countries in which the -------------------------------
entity has +security holders who will
not be sent new issue documents
Note: Security holders must be told how their
entitlements are to be dealt with.
Cross reference: rule 7.7. -------------------------------
19 Closing date for receipt of -------------------------------
acceptances or renunciations
-------------------------------
20 Names of any underwriters -------------------------------
-------------------------------
21 Amount of any underwriting fee or -------------------------------
commission
-------------------------------
22 Names of any brokers to the issue -------------------------------
23 Fee or commission payable to the -------------------------------
broker to the issue
-------------------------------
24 Amount of any handling fee ------------------------------
payable to brokers who lodge
acceptances or renunciations on
behalf of +security holders -------------------------------
25 If the issue is contingent on -------------------------------
+security holders' approval, the date
of the meeting -------------------------------
26 Date entitlement and acceptance -------------------------------
form and prospectus or Product
Disclosure Statement will be sent to
persons entitled -------------------------------
27 If the entity has issued options, -------------------------------
and the terms entitle option holders to
participate on exercise, the date on
which notices will be sent to option
holders -------------------------------
28 Date rights trading will begin (if -------------------------------
applicable)
-------------------------------
29 Date rights trading will end (if -------------------------------
applicable)
-------------------------------
30 How do +security holders sell their -------------------------------
entitlements in full through a broker?
------------------------------
--------------------------------------------------------------------------------
+See chapter 19 for defined terms.
Appendix 3B Page 4 1/1/2003
Appendix 3B
New issue announcement
-------------------------------------------------------------------------------
31 How do +security holders sell part --------------------------------
of their entitlements through a broker
and accept for the balance?
--------------------------------
32 How do +security holders dispose --------------------------------
of their entitlements (except by sale
through a broker)? --------------------------------
33 +Despatch date --------------------------------
--------------------------------
Part 3 - Quotation of securities
You need only complete this section if you are applying for quotation of
securities
34 Type of securities
(tick one)
(a) [X} Securities described in Part 1
(b) [ ] All other securities
Example: restricted securities at the end of the escrowed
period, partly paid securities that become fully paid,
employee incentive share securities when restriction ends,
securities issued on expiry or conversion of convertible
securities
Entities that have ticked box 34(a)
Additional securities forming a new class of securities
Tick to indicate you are providing the information or
documents
35 [ ] If the +securities are +equity securities, the names of the 20
largest holders of the additional +securities, and the number
and percentage of additional +securities held by those holders
36 [ ] If the +securities are +equity securities, a distribution
schedule of the additional +securities setting out the number
of holders in the categories
1 - 1,000
1,001 - 5,000
5,001 - 10,000
10,001 - 100,000
100,001 and over
37 [ ] A copy of any trust deed for the additional +securities
--------------------------------------------------------------------------------
+ See chapter 19 for defined terms.
1/1/2003 Appendix 3B Page 5
Appendix 3B
New issue announcement
--------------------------------------------------------------------------------
Entities that have ticked box 34(b)
38 Number of securities for which ------------------------------
+quotation is sought
------------------------------
39 Class of +securities for which ------------------------------
quotation is sought
------------------------------
40 Do the +securities rank equally ------------------------------
in all respects from the date of
allotment with an existing +class of
quoted +securities? ------------------------------
If the additional securities do not ------------------------------
rank equally, please state:
- the date from which they do
- the extent to which they participate
for the next dividend, (in
the case of a trust, distribution)
or interest payment
- the extent to which
they do not rank equally, other than
in relation to the next dividend,
distribution or interest payment
------------------------------
41 Reason for request for quotation ------------------------------
now
Example: In the case of restricted securities,
end of restriction period
(if issued upon conversion of
another security, clearly identify that
other security) ------------------------------
----------------- ------------
Number +Class
----------------- ------------
42 Number and +class of all
+securities quoted on ASX
(including the
securities in clause 38)
----------------- ------------
--------------------------------------------------------------------------------
+ See chapter 19 for defined terms.
Appendix 3B Page 6 1/1/2003
Appendix 3B
New issue announcement
--------------------------------------------------------------------------------
Quotation agreement
1 +Quotation of our additional +securities is in ASX's absolute discretion.
ASX may quote the +securities on any conditions it decides.
2 We warrant the following to ASX.
- The issue of the +securities to be quoted complies with the law and is
not for an illegal purpose.
- There is no reason why those +securities should not be granted
+quotation.
- An offer of the +securities for sale within 12 months after their
issue will not require disclosure under section 707(3) or section
1012C(6) of the Corporations Act.
Note: An entity may need to obtain appropriate warranties from
subscribers for the securities in order to be able to give this
warranty
- Section 724 or section 1016E of the Corporations Act does not apply to
any applications received by us in relation to any +securities to be
quoted and that no-one has any right to return any +securities to be
quoted under sections 737, 738 or 1016F of the Corporations Act at the
time that we request that the +securities be quoted.
- We warrant that if confirmation is required under section 1017F of the
Corporations Act in relation to the +securities to be quoted, it has
been provided at the time that we request that the +securities be
quoted.
- If we are a trust, we warrant that no person has the right to return
the +securities to be quoted under section 1019B of the Corporations
Act at the time that we request that the +securities be quoted.
--------------------------------------------------------------------------------
+ See chapter 19 for defined terms.
1/1/2003 Appendix 3B Page 7
Appendix 3B
New issue announcement
--------------------------------------------------------------------------------
3 We will indemnify ASX to the fullest extent permitted by law in respect of
any claim, action or expense arising from or connected with any breach of
the warranties in this agreement.
4 We give ASX the information and documents required by this form. If any
information or document not available now, will give it to ASX before
+quotation of the +securities begins. We acknowledge that ASX is relying on
the information and documents. We warrant that they are (will be) true and
complete.
Sign here: /s/Richard Revelins Date: 13 March 2003
(Director/Company secretary)
Print name: RICHARD REVELINS
== == == == ==
-------------------------------------------------------------------------------
+ See chapter 19 for defined terms.
Appendix 3B Page 8 1/1/2003
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
PRANA BIOTECHNOLOGY LIMITED
---------------------------
(Registrant)
By: /s/Phillip Hains
-------------------------------
Phillip Hains
Administrative Officer
Date: March 18, 2003